Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of AZD4547 in Japanese Patients With Advanced Solid Malignancies
jRCT2080221259Phase 1
- Sponsor
- AstraZeneca
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fexagratinib in Non-hematologic malignancy, sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of AZD4547, Pharmacokinetics of AZD4547 and 1 more.
02
Drugs
fexagratinib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080221259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221259.